| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reviews |
Authors' Affiliations: Departments of 1 Pathology, 2 Medicine, and 3 Radiation Oncology, Duke University Medical Center, Durham, North Carolina
Requests for reprints: Mark W. Dewhirst, Department of Radiation Oncology, Duke University Medical Center, Durham, NC 22710. Phone: 919-684-4180; Fax: 919-684-8718; E-mail: dewhirst{at}radonc.duke.edu.
Erythropoietin (Epo) has long been known to be the principal hematopoietic growth factor that regulates cellular proliferation and differentiation along the erythroid lineage. Recent studies have shown that Epo is a pleiotropic cytokine that is proangiogenic and exerts broad tissue-protective effects in diverse nonhematopoietic organs. Recombinant Epo (rEpo) has been widely used in the clinic to prevent or treat malignancy-associated anemia. A series of clinical trials have documented the efficacy of rEpo in reducing RBC transfusion requirements and improving quality of life in cancer patients, and a recent meta-analysis suggested a positive effect on survival. However, two randomized trials reported negative outcomes with rEpo, as patients in the rEpo arm fared worse than their placebo-treated counterparts with respect to progression-free survival. The expression of Epo receptor (EpoR) in cancer cells has raised the possibility that exogenous rEpo may exert direct effects on tumor cells associated with the potential for stimulation of proliferation, inhibition of apoptosis, or modulation of sensitivity to chemoradiation therapy. The presence of an autocrine-paracrine Epo-EpoR system in tumors and potential effects of Epo on tumor microenvironment and angiogenesis are consistent with a complex biology for Epo-EpoR signaling in cancer that requires further research. This review describes Epo and EpoR biology, focusing on the pleiotropic effects of Epo on nonhematopoietic tissues as well as the expression and function of EpoR in cancer cells.
This article has been cited by other articles:
|
|
 |
|
  M. O. Arcasoy Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives Clin. Cancer Res., August 1, 2008; 14(15): 4685 - 4690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bose and K. B. Udupa Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals Am J Physiol Cell Physiol, August 1, 2008; 295(2): C394 - C405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mannello and G. A. M. Tonti Erythropoietin and Its Receptor in Breast Cancer: Putting Together the Pieces of the Puzzle Oncologist, July 1, 2008; 13(7): 761 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. May and F. R. Khuri Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion Cancer Res., June 1, 2008; 68(11): 4013 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia JAMA, February 27, 2008; 299(8): 914 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. May and F. R. Khuri Role of Erythropoietin-stimulating Agents in the Outcomes of Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 140 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Pelekanou, M. Kampa, M. Kafousi, K. Dambaki, K. Darivianaki, T. Vrekoussis, E. Sanidas, D. D. Tsiftsis, E. N. Stathopoulos, and E. Castanas Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2016 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kase, W. Saito, K. Ohgami, K. Yoshida, N. Furudate, A. Saito, M. Yokoi, M. Kase, and S. Ohno Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy Br. J. Ophthalmol., October 1, 2007; 91(10): 1376 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Saintigny, B. Besse, P. Callard, A.-C. Vergnaud, S. Czernichow, M. Colombat, P. Girard, P. Validire, J.-L. Breau, J.-F. Bernaudin, et al. Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non Small Cell Lung Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4825 - 4831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Laurie, K Ding, M Whitehead, R Feld, N Murray, F. Shepherd, and L Seymour The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group Ann. Onc., June 1, 2007; 18(6): 1051 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications Am. J. Pathol., January 1, 2007; 170(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Lai and J. R. Grandis Understanding the Presence and Function of Erythropoietin Receptors on Cancer Cells J. Clin. Oncol., October 10, 2006; 24(29): 4675 - 4676. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
